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licenses/by/4.0/).Abstract Introduction: Airway micro-aspiration might contribute to the proposed associa-
tions between gastroesophageal reflux disease (GERD) and some lung diseases, including lung
cancer. This study aimed to examine the hypothesis that antireflux surgery decreases the risk
of small cell carcinoma, squamous cell carcinoma and adenocarcinoma of the lung differently
depending on their location in relation to micro-aspiration.
Methods: Population-based cohort study including patients having undergone antireflux sur-
gery during 1980e2014 in Denmark, Finland, Iceland, Norway or Sweden. Patients havingintestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Retzius Street
den.
i.se (J. Lagergren).
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undergone antireflux surgery were compared with two groups: 1) the corresponding back-
ground population, by calculating standardised incidence ratios (SIRs) with 95% confidence
intervals (CIs) and 2) non-operated GERD-patients, by calculating hazard ratios (HRs) with
95% CIs using multivariable Cox regression with adjustment for sex, age, calendar period,
country, chronic obstructive pulmonary disease and obesity diagnosis or type 2 diabetes.
Results: Among all 812,617 GERD-patients, 46,996 (5.8%) had undergone antireflux surgery.
The SIRs were statistically significantly decreased for small cell carcinoma (SIR Z 0.57, 95%
CI 0.41e0.77) and squamous cell carcinoma (SIR Z 0.75, 95% CI 0.60e0.92), but not for
adenocarcinoma of the lung (SIRZ 0.90, 95% CI 0.76e1.06). The HRs were also below unity
for small cell carcinoma (HR Z 0.63, 95% CI 0.44e0.90) and squamous cell carcinoma
(HR Z 0.80, 95% CI 0.62e1.03), but not for adenocarcinoma of the lung (HR Z 1.03,
95% CI 0.84e1.26). Analyses restricted to patients with objective GERD (reflux oesophagitis
or Barrett’s oesophagus) showed similar results.
Conclusions: This all-Nordic study indicates that patients who undergo antireflux surgery are
at decreased risk of small cell carcinoma and squamous cell carcinoma of the lung, but not of
adenocarcinoma of the lung.
ª 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Gastroesophageal reflux disease (GERD), characterised
by troublesome heartburn or regurgitation or GERD-
specific complications, affects 20% of adults in Western
countries [1e4]. Reflux of duodenogastric contents
might result in micro-aspiration to the airways [5e7],
where it can cause lung diseases, i.e. asthma, chronic
obstructive pulmonary disease, pneumonia, idiopathic
pulmonary fibrosis and bronchiolitis obliterans syn-
drome [6e10]. Therefore, in addition to the known as-
sociations between GERD and cancer of the
oesophagus, larynx and pharynx [11e14], an association
with lung cancer has been suggested [15e18]. Yet, no
study has examined if antireflux therapy counteracts
lung cancer. Medication with proton pump inhibitors
reduces the acidity of the duodenogastric contents and
relieves symptoms of heartburn but does not stop non-
acidic reflux, regurgitation or aspiration, why airway
symptoms may still persist or arise [19]. Antireflux sur-
gery, on the other hand, accomplishes a barrier to acidic
and non-acidic reflux and can reduce asthma symptoms
in GERD-patients [20e22] and improve pulmonary
function in lung transplantation patients [23e25]. While
lung cancer has one of the highest cancer incidences and
mortalities worldwide, the incidence of lung cancer in
the Nordic countries is among the lowest in Europe
[26,27]. The three main histological types of lung cancer,
i.e. small cell carcinoma, squamous cell carcinoma and
adenocarcinoma, have different etiological, clinical and
molecular characteristics, although tobacco smoking is a
shared risk factor [28]. Small cell carcinoma and squa-
mous cell carcinoma primarily arise in the central air-
ways, i.e. closer to any aspiration, while
adenocarcinoma mostly arise more peripherally [29].
This multinational Nordic study aimed to test thehypothesis that antireflux surgery decreases the risk of
small cell carcinoma, squamous cell carcinoma and
adenocarcinoma of the lung in GERD-patients, and
that this decrease is stronger for small cell carcinoma
and squamous cell carcinoma than for adenocarcinoma
because of the differences in proximity to aspirated
refluxate.
2. Methods
2.1. Design
This was a population-based cohort study based on
well-established and nationwide health data registries in
the five Nordic countries, i.e. Denmark, Finland, Ice-
land, Norway and Sweden (alphabetic order). The
overall study period was from 1980 through 2014, but
with different start and end years in each country. The
study separately investigated the risk of small cell car-
cinoma, squamous cell carcinoma and adenocarcinoma
of the lung after antireflux surgery for GERD. Ethical
and data permissions were retrieved from all relevant
authorities within each country [30].
2.2. Cohorts
The source cohort, entitled the Nordic Antireflux Sur-
gery Cohort (NordASCo), has been presented in detail
in a cohort profile [30]. In summary, data were collected
from health data registries, i.e. the patient registries,
cancer registries and cause of death registries in the
Nordic countries. The similarity in the structure of the
health data registries in the Nordic countries, combined
with the well-established system of the unique personal
identity number assigned to each resident in all Nordic
countries, allowed linkages of the individuals’ data
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[30,31].
The patients in the study cohort, who had GERD
documented from in-hospital and specialised out-patient
care in any of the national patient registries, were be-
tween 18 and 95 years of age, and without any lung
cancer before the GERD diagnosis. A sub-cohort was
restricted to patients with objective GERD, i.e. objec-
tively determined reflux oesophagitis or Barrett’s
oesophagus (a columnar cell metaplasia preceding
oesophageal adenocarcinoma).
The codes defining GERD, objective GERD and
antireflux surgery in the patient registries are presented
in Supplementary Table 1. While complete nationwide
coverage of the patient registries was reached in the
1970s (Finland), 1978 (Denmark), 1987 (Sweden), 1999
(Iceland) and 2008 (Norway), this study started from
1980, from when data on antireflux surgery was avail-
able. The data in these registries have high validity with
most diagnoses and operations having a positive pre-
dictive value close to 100% [32e34]. The diagnosis of
GERD has not been separately validated in the Nordic
patient registries; however, the diagnosis codes that
correspond to reflux oesophagitis and Barrett’s
oesophagus require confirmation by endoscopy and
histology, which should counteract misclassification.
Norwegian GERD patients were excluded from the sub-
analyses of objective GERD because four-character sub-
categories of diagnosis codes were not available in the
Norwegian patient registry.2.3. Outcomes
The three outcomes, i.e. small cell carcinoma, squamous
cell carcinoma and adenocarcinoma of the lung, were
identified in the cancer registries by their relevant diag-
nosis codes (Supplementary Table 2). The cancer regis-
tries provided data on tumour topography,
morphology and diagnosis date. To reduce misclassifi-
cation, histological sub-types that were ill-defined, or
that potentially represented poor or undifferentiated
forms of lung cancer were excluded. All Nordic cancer
registries have been nationwide since their initiation in
1943 (Denmark), 1953 (Norway), 1953 (Finland), 1955
(Iceland) and 1958 (Sweden). Validation studies of these
registries have consistently shown high completeness
(98.2%) and accuracy (93.8%) [35]. The cancer reg-
istries provided data on cancer incidence in the study
cohort. Combined with the registries of the total pop-
ulations, the cancer registries also provided data on
population count and number of lung cancers by his-
tological type in the general background populations by
age, sex and calendar year in each Nordic country,
which enabled calculation of these tumours’ incidence
rates in the background population.2.4. Statistical analysis
When calculating person-years at risk, the first year of
follow-up was excluded to avoid detection bias, i.e.
earlier tumour detection because of the GERD diag-
nosis or the antireflux surgery. Person-years at risk in
the antireflux surgery groups with any GERD or
objective GERD were accumulated from 1 year after
surgery until the date of any lung cancer, death or end of
study period, whichever occurred first. Person-years at
risk in the non-operated groups with any GERD or
objective GERD were accumulated from 1 year after the
date of GERD until the first occurrence of any type of
lung cancer, death, end of the study period or the date of
admission for antireflux surgery. In this way, GERD
patients who underwent antireflux surgery were
censored from the non-operated group at the date of
admission for antireflux surgery, and 1 year after that
date included in the antireflux surgery group instead.
Two statistical approaches were used to calculate the
measures of relative risks. The incidence in the cohort
was first compared with the incidence of the corre-
sponding background population by calculating stand-
ardised incidence ratios (SIRs) and 95% confidence
intervals (CIs). The observed number of small cell car-
cinomas, squamous cell carcinomas or adenocarcinomas
of the lung in the patient cohorts was divided by the
expected number among individuals of the correspond-
ing sex (male or female), age group (5-year
categories) and calendar period (5-year categories).
SIRs were computed for the overall period (>1e34
years) and separately for the specific follow-up cate-
gories, i.e. >1e5, >5e10, >10e15 and >15 years. It was
not possible to exclude the cases of small cell carci-
nomas, squamous cell carcinomas or adenocarcinomas
in the cohort from the background population, but the
low incidence of these tumours means that the results
would not be much influenced and any influence would
dilute estimates rather than contribute to associations.
In the second statistical approach, the risk of lung
cancer in the antireflux surgery groups with any GERD
and objective GERD were compared with the non-
operated groups with any GERD or objective GERD,
using the non-operated groups as references. Multivar-
iable Cox regression was used to calculate hazard ratios
(HRs) and 95% CIs, adjusted for six potential con-
founders: sex (male or female), age (continuous), cal-
endar period (1980e1989, 1990e1999 or 2000e2014),
country (Denmark, Finland, Iceland, Norway or Swe-
den), chronic obstructive pulmonary disease (yes or
no) and obesity diagnosis or diabetes mellitus type 2 (yes
or no). Chronic obstructive pulmonary disease was used
as a marker of tobacco smoking, whereas obesity diag-
nosis or diabetes mellitus type 2 represented obesity in
the models. These conditions are chronic and were thus
measured without time restrictions. The follow-up
Table 1
Characteristics of individuals with gastroesophageal reflux disease
having undergone antireflux surgery or not.
Antireflux
surgery
Number (%)
No antireflux
surgery
Number (%)
Any gastroesophageal reflux disease
Total
Patientsa 46,996 (100) 778,943 (100)
Person-years of follow-up 555,748 5,011,842
Sex
Male 26,475 (56.3) 378,245 (48.6)
Female 20,521 (43.7) 400,698 (51.4)
Age at inclusion
<50 years 22,088 (47.0) 256,401 (32.9)
50e<65 years 18,218 (38.8) 237,215 (30.5)
65 years 6690 (14.2) 285,327 (36.6)
Chronic obstructive pulmonary
disease
3821 (8.1) 69,889 (9.0)
Obesity diagnosis 2267 (4.8) 38,850 (5.0)
Diabetes mellitus type 2 3960 (8.4) 78,221 (10.0)
Lung cancer 273 (0.6) [100] 3650 (0.5) [100]
Small cell carcinoma 43 [15.8] 724 [19.8]
Squamous cell carcinoma 88 [32.2] 1152 [31.6]
Adenocarcinoma 142 [52.0] 1774 [48.6]
Objective gastroesophageal reflux disease (reflux oesophagitis or
Barrett’s oesophagus)
Total
Patients 34,752 (100) 242,292 (100)
Person-years of follow-up 425,008 1,993,691
Sex
Male 20,063 (57.7) 133,703 (55.2)
Female 14,689 (42.3) 108,589 (44.8)
Age at inclusion
<50 years 16,731 (48.1) 76,808 (31.7)
50e<65 years 13,758 (39.6) 76,837 (31.7)
65 years 4263 (12.3) 88,647 (36.6)
Chronic obstructive pulmonary
disease
2797 (8.0) 26,746 (11.0)
Obesity diagnosis 1670 (4.8) 14,248 (5.9)
Diabetes mellitus type 2 3024 (8.7) 30,608 (12.6)
Lung cancer 191 (0.5) [100] 1491 (0.6) [100]
Small cell carcinoma 31 [16.2] 313 [21.0]
Squamous cell carcinoma 59 [30.9] 472 [31.7]
Adenocarcinoma 101 [52.9] 674 [45.2]
a Among the non-operated patients, 13,322 were also included in the
operated group after they were censored from the non-operated group
at the date of admission to antireflux surgery.
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the calculation of SIRs, i.e. >1e34, >1e5, >5e10,
>10e15 and >15 years. The proportionality hazards
assumption was examined by plotting log (-log) survival
function versus log analysis time. The assumption was
met for small cell carcinoma, but not for squamous cell
carcinoma or adenocarcinoma, which was solved by the
stratification into follow-up time periods.
The data management and statistical analyses fol-
lowed a pre-defined study protocol and were conducted
using IBM SPSS Statistics version 24 (IBM Corp,
Armonk, NY, USA).
3. Results
3.1. Patients
Of all 812,617 cohort patients with any GERD
(5,011,842 person-years at risk), 46,996 (5.8%) under-
went antireflux surgery (555,748 person-years at risk).
Among patients in the non-operated group, 13,332 were
censored and included in the antireflux surgery group
from the date of admission to antireflux surgery. Of
269,318 patients with objective GERD, 34,752 (12.9%)
underwent antireflux surgery (Table 1). Among patients
with any GERD, 3650 (0.5%) developed lung cancer
during follow-up in the non-operated group and 273
(0.6%) in the operated group. In patients with objective
GERD, 1491 (0.6%) and 191 (0.5%) developed lung
cancer in the non-operated and operated group,
respectively (Table 1).
3.2. Operated patients with gastroesophageal reflux
disease compared with the background population
Table 2A shows the SIRs after antireflux surgery for any
GERD. The overall SIRs were particularly decreased
for small cell carcinoma (SIR 0.57, 95% CI 0.41e0.77)
and also for squamous cell carcinoma (SIR 0.75, 95% CI
0.60e0.92), but not for adenocarcinoma of the lung
(SIR 0.90, 95% CI 0.76e1.06). The SIRs did not
decrease with longer follow-up time after antireflux
surgery for any of the three histological types. In the
analyses of patients with objective GERD, most esti-
mates were similar to those in the entire GERD cohort
(Table 2B).
3.3. Non-operated patients with gastroesophageal reflux
disease compared with the background population
The SIRs were lower for small cell carcinoma (SIR 0.83,
95% CI 0.77e0.89), squamous cell carcinoma (SIR 0.87,
95% CI 0.82e0.92) and adenocarcinoma (SIR 0.83, 95%
CI 0.80e0.87) (Table 2A). The SIRs did not change
much over follow-up periods, and the results were
similar for objective GERD (Table 2B).3.4. Operated compared with non-operated patients with
gastroesophageal reflux disease
Table 3A presents the HRs for the group who had un-
dergone antireflux surgery for any GERD compared
with the non-operated group with any GERD. The
overall adjusted HRs after antireflux surgery were
decreased for small cell carcinoma (HR 0.63, 95% CI
0.44e0.90), decreased without statistical significance for
squamous cell carcinoma (HR 0.80, 95% CI 0.62e1.03),
and not decreased for adenocarcinoma (HR 1.03, 95%
CI 0.84e1.26). The HRs did not decrease over time after
antireflux surgery for any of the histological types, but
for small cell carcinoma, the point estimates remained
Table 2A
Risk of lung cancer by histological type among patients with any gastroesophageal reflux disease compared with the corresponding background
population, presented as standardised incidence ratios (SIRs) with 95% confidence intervals (95% CIs).
Small cell carcinoma Squamous cell carcinoma Adenocarcinoma
Follow-up (years) Total (n) Person-years Cases (n) SIR (95% CI) Cases (n) SIR (95% CI) Cases (n) SIR (95% CI)
Antireflux surgery
>1e34 46,966 555,748 43 0.57 (0.41e0.77) 88 0.75 (0.60e0.92) 142 0.90 (0.76e1.06)
>1e5 46,966 176,254 14 0.75 (0.41e1.26) 16 0.59 (0.34e0.95) 24 0.74 (0.47e1.09)
>5e10 40,618 179,507 7 0.31 (0.12e0.64) 25 0.73 (0.47e1.08) 42 0.94 (0.68e1.27)
>10e15 30,142 117,401 11 0.62 (0.31e1.11) 19 0.67 (0.40e1.05) 40 1.00 (0.72e1.37)
>15 16,605 82,585 11 0.68 (0.34e1.22) 28 1.00 (0.66e1.44) 36 0.89 (0.62e1.23)
No antireflux surgery
>1e34 778,943 5,011,842 724 0.83 (0.77e0.89) 1152 0.87 (0.82e0.92) 1774 0.83 (0.80e0.87)
>1e5 778,943 2,406,216 332 0.86 (0.77e0.96) 550 0.95 (0.87e1.03) 786 0.88 (0.82e0.94)
>5e10 437,681 1,532,301 200 0.77 (0.67e0.89) 322 0.81 (0.73e0.91) 562 0.87 (0.80e0.95)
>10e15 212,288 707,015 114 0.82 (0.67e0.98) 160 0.76 (0.64e0.88) 274 0.76 (0.68e0.86)
>15 83,989 366,310 78 0.88 (0.69e1.10) 120 0.87 (0.72e1.04) 152 0.67 (0.57e0.79)
Table 2B
Risk of lung cancer by histological type among patients with objective gastroesophageal reflux disease (reflux oesophagitis or Barrett’s
oesophagus) compared to the corresponding background population, presented as standardised incidence ratios (SIRs) with 95% confidence
intervals (95% CIs).
Small cell carcinoma Squamous cell carcinoma Adenocarcinoma
Follow-up (years) Total (n) Person-years Cases (n) SIR (95% CI) Cases (n) SIR (95% CI) Cases (n) SIR (95% CI)
Antireflux surgery
>1e34 34,752 425,008 31 0.58 (0.39e0.82) 59 0.70 (0.53e0.90) 101 0.88 (0.72e1.07)
>1e5 34,752 132,274 9 0.69 (0.32e1.31) 8 0.42 (0.18e0.83) 14 0.61 (0.34e1.03)
>5e10 31,066 138,898 4 0.24 (0.07e0.62) 22 0.88 (0.55e1.33) 29 0.87 (0.58e1.25)
>10e15 23,387 91,544 8 0.61 (0.26e1.20) 15 0.71 (0.40e1.17) 28 0.93 (0.62e1.35)
>15 12,986 62,292 10 0.92 (0.44e1.69) 14 0.72 (0.39e1.21) 30 1.06 (0.71e1.51)
No antireflux surgery
>1e34 242,292 1,993,691 313 0.88 (0.78e0.98) 472 0.84 (0.77e0.92) 674 0.81 (0.75e0.87)
>1e5 242,292 808,109 121 0.92 (0.76e1.10) 190 0.91 (0.76e1.05) 239 0.83 (0.73e0.95)
>5e10 165,876 639,932 80 0.71 (0.56e0.88) 144 0.82 (0.69e0.97) 202 0.77 (0.67e0.88)
>10e15 93,809 329,116 63 0.98 (0.75e1.25) 79 0.79 (0.63e0.98) 137 0.86 (0.73e1.02)
>15 43,044 216,534 49 1.04 (0.77e1.37) 59 0.77 (0.59e1.00) 96 0.78 (0.63e0.95)
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not much influenced by adjustment for chronic
obstructive pulmonary disease (Table 3A). The analyses
of patients with objective GERD showed similar results
as to the total GERD cohort, although most point es-
timates were slightly lower (Table 3B). The overall HRs
were 0.55 (95% CI 0.36e0.84) for small cell carcinoma,
0.73 (95% CI 0.53e1.01) for squamous cell
carcinoma and 0.95 (95% CI 0.74e1.21) for adenocar-
cinoma, and all point estimates were below 1
throughout the follow-up (Table 3B).4. Discussion
This study indicates that patients who undergo antire-
flux surgery for GERD have decreased risks of small cell
carcinoma and squamous cell carcinoma, but not of
adenocarcinoma of the lung, compared with the back-
ground population as well as the non-operated patients
with GERD.Among methodological strengths of this study are the
population-based design and the large cohort size,
including most patients with a recorded diagnosis of
GERD and those who had undergone antireflux surgery
for GERD in any of the five Nordic countries. The long
(up to 34 years) and complete follow-up are other ad-
vantages. The similar results from the analysis of the any
GERD group and the objective GERD group indicate a
low level of misclassification of GERD. The similar
findings when comparing the antireflux surgery group
with both the background population and non-operated
patients with GERD also suggests validity of the results.
A weakness is the risk of residual confounding despite
adjustment for several confounders. The unavailability
of direct data on tobacco smoking might be particularly
relevant. Individuals selected for antireflux surgery
might be less likely to be heavy tobacco smokers, and
smoking is a risk factor for GERD and the three his-
tological types of lung cancer under study [4,36]. How-
ever, a strong influence of confounding by smoking is
less likely because of the weak association between
Table 3A
Risk of lung cancer by histological type among patients with any gastroesophageal reflux disease, comparing antireflux surgery with no such
surgery and presented as hazard ratios (HRs) with 95% confidence intervals (CIs) from the Cox proportional hazard analyses.
Follow-up (years) No antireflux surgery Antireflux surgery
Cases (n) HR (95% CI) Cases (n) Crude HR (95% CI) Adjusteda HR (95% CI) Adjustedb HR (95% CI)
Small cell carcinoma
>1e34 724 1.00 (Reference) 43 0.51 (0.37e0.69) 0.64 (0.45e0.90) 0.63 (0.44e0.90)
>1e5 332 1.00 (Reference) 14 0.58 (0.34e0.99) 0.80 (0.43e1.48) 0.81 (0.44e1.49)
>5e10 200 1.00 (Reference) 7 0.30 (0.14e0.64) 0.38 (0.16e0.90) 0.37 (0.16e0.89)
>10e15 114 1.00 (Reference) 11 0.57 (0.31e1.06) 0.67 (0.32e1.40) 0.66 (0.32e1.37)
>15 78 1.00 (Reference) 11 0.62 (0.33e1.17) 0.72 (0.37e1.40) 0.71 (0.37e1.38)
Squamous cell carcinoma
>1e34 1152 1.00 (Reference) 88 0.66 (0.53e0.82) 0.81 (0.63e1.04) 0.80 (0.62e1.03)
>1e5 550 1.00 (Reference) 16 0.40 (0.24e0.66) 0.58 (0.32e1.04) 0.58 (0.33e1.03)
>5e10 322 1.00 (Reference) 25 0.67 (0.44e1.00) 0.74 (0.45e1.22) 0.74 (0.45e1.21)
>10e15 160 1.00 (Reference) 19 0.71 (0.44e1.14) 0.87 (0.50e1.51) 0.86 (0.50e1.49)
>15 120 1.00 (Reference) 28 1.02 (0.68e1.54) 1.16 (0.74e1.81) 1.13 (0.72e1.77)
Adenocarcinoma
>1e34 1774 1.00 (Reference) 142 0.70 (0.58e0.82) 1.04 (0.85e1.27) 1.03 (0.84e1.26)
>1e5 786 1.00 (Reference) 24 0.42 (0.28e0.62) 0.84 (0.53e1.33) 0.83 (0.52e1.32)
>5e10 562 1.00 (Reference) 42 0.64 (0.47e0.87) 1.08 (0.75e1.55) 1.07 (0.74e1.54)
>10e15 274 1.00 (Reference) 40 0.88 (0.63e1.22) 1.10 (0.74e1.63) 1.09 (0.73e1.62)
>15 152 1.00 (Reference) 36 1.05 (0.73e1.51) 1.13 (0.76e1.69) 1.12 (0.75e1.67)
a Adjusted for sex, age (continuous), calendar period, country, obesity diagnosis and diabetes mellitus type 2.
b Adjusted for sex, age (continuous), calendar period, country, obesity diagnosis, diabetes mellitus type 2 and chronic obstructive pulmonary
disease.
M. Yanes et al. / European Journal of Cancer 138 (2020) 80e88 85smoking and GERD [4,37], and by the lack of influence
of the adjustment for chronic obstructive pulmonary
disease in the Cox regression analyses. Chronic
obstructive pulmonary disease is namely strongly asso-
ciated with smoking duration and intensity [38]. Con-
founding by other variables cannot be excluded, butTable 3B
Risk of lung cancer by histological type among patients with objectiv
oesophagus), comparing antireflux surgery with no such surgery and presen
the Cox proportional hazard analyses.
Follow-up (years) No antireflux surgery Antireflux surgery
Cases (n) HR (95% CI) Cases (n) Crude
Small cell carcinoma
>1e34 313 1.00 (Reference) 31 0.45 (0
>1e5 121 1.00 (Reference) 9 0.46 (0
>5e10 80 1.00 (Reference) 4 0.23 (0
>10e15 63 1.00 (Reference) 8 0.45 (0
>15 49 1.00 (Reference) 10 0.71 (0
Squamous cell carcinoma
>1e34 472 1.00 (Reference) 59 0.58 (0
>1e5 190 1.00 (Reference) 8 0.26 (0
>5e10 144 1.00 (Reference) 22 0.71 (0
>10e15 79 1.00 (Reference) 15 0.69 (0
>15 59 1.00 (Reference) 14 0.84 (0
Adenocarcinoma
>1e34 674 1.00 (Reference) 101 0.67 (0
>1e5 239 1.00 (Reference) 14 0.36 (0
>5e10 202 1.00 (Reference) 29 0.66 (0
>10e15 137 1.00 (Reference) 28 0.73 (0
>15 96 1.00 (Reference) 30 1.10 (0
a Adjusted for sex, age (continuous), calendar period, country, obesity d
b Adjusted for sex, age (continuous), calendar period, country, obesity d
disease.except for smoking, the only established risk factors for
GERD are obesity and heredity for GERD, which are
not associated with the risk of lung cancer and should
therefore not confound the results. Therefore, it was
expected that adjustment for obesity diagnoses did not
influence the HRs. The results from a study examininge gastroesophageal reflux disease (reflux oesophagitis or Barrett’s
ted as hazard ratios (HRs) with 95% confidence intervals (CIs) from
HR (95% CI) Adjusteda HR (95% CI) Adjustedb HR (95% CI)
.31e0.65) 0.54 (0.35e0.83) 0.55 (0.36e0.84)
.23e0.90) 0.51 (0.23e1.15) 0.52 (0.23e1.16)
.08e0.63) 0.34 (0.11e1.09) 0.35 (0.11e1.09)
.22e0.94) 0.54 (0.22e1.29) 0.54 (0.23e1.30)
.36e1.40) 0.88 (0.43e1.82) 0.88 (0.43e1.81)
.44e0.76) 0.73 (0.53e1.01) 0.73 (0.53e1.01)
.13e0.52) 0.42 (0.19e0.95) 0.43 (0.19e0.96)
.45e1.11) 0.74 (0.42e1.31) 0.75 (0.43e1.32)
.39e1.19) 0.91 (0.48e1.73) 0.91 (0.48e1.73)
.47e1.51) 0.93 (0.49e1.76) 0.92 (0.48e1.74)
.55e0.83) 0.94 (0.74e1.21) 0.95 (0.74e1.21)
.21e0.61) 0.75 (0.40e1.39) 0.74 (0.40e1.38)
.45e0.98) 1.05 (0.66e1.66) 1.05 (0.66e1.66)
.49e1.10) 0.85 (0.52e1.39) 0.86 (0.53e1.40)
.73e1.66) 1.14 (0.72e1.82) 1.14 (0.72e1.82)
iagnosis and diabetes mellitus type 2.
iagnosis, diabetes mellitus type 2 and chronic obstructive pulmonary
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showed no influence of antireflux surgery, further indi-
cating that the antireflux surgery group was not selected
compared with the background population or the non-
operated group with GERD [39]. Another limitation is
the potential influence of recurrence of GERD after
antireflux surgery, which occurred in 17.7% of Swedish
patients included in the cohort [40]. This exposure
misclassification should not contribute to the overall
associations, but rather dilute them. However, it could
explain the lack of risk reductions over time after anti-
reflux surgery. The lack of data on specific surgical
codes prohibited separate analyses of specific types of
antireflux surgery, but the commonly used antireflux
surgery procedures have similar effects on GERD [41].
Histological misclassification of squamous cell carci-
noma and adenocarcinoma of the lung is possible due to
pathologic sub-typing disagreement. However, this has
been shown to be limited and would only attenuate the
reported risk estimates, not explain them [42,43]. The
prevalence of GERD is comparable between Nordic
countries and other Western countries [1,2], suggesting
that the findings could be generalised to Western
populations.
To our knowledge, no other study has investigated if
antireflux surgery influences the risk of lung cancer. The
decreased overall risks of small cell carcinoma and
squamous cell carcinoma of the lung suggest a protec-
tive role of antireflux surgery. During follow-up, the risk
reduction seemed more pronounced within 5e10 years
for small cell carcinoma and 1e5 years for squamous
cell carcinoma. A cancer preventive effect of antireflux
surgery is expected to increase with longer follow-up;
therefore, a cautious interpretation is necessary because
of the lack of trend of further reduction in risk by time
after surgery, although recurrence of GERD after sur-
gery might be the explanation for this pattern [40]. More
research is clearly needed to confirm these findings.
Nevertheless, it is biologically plausible that antireflux
surgery counteracts micro-aspiration of acidic and non-
acidic duodenogastric content in patients with reflux,
which may reduce inflammatory insults and subsequent
oncogenic processes. This mechanism gains support by
the finding that antireflux surgery in lung trans-
plantation patients with GERD reduces pepsin levels in
the lungs [44]. As described in detail elsewhere, antire-
flux medication was used by 92.1% of a sample of
199,466 non-operated GERD patients included in the
present cohort [39]. The lower risk of lung cancer after
antireflux surgery compared with antireflux medication
use in the non-operated GERD groups is
expected because antireflux medication does not prevent
airway aspiration well. The findings of decreased risks of
small cell carcinoma and squamous cell carcinoma, but
not of adenocarcinoma, following antireflux surgery are
well in line with the study hypotheses. This could be due
to anatomical reasons, with small cell carcinoma andsquamous cell carcinoma primarily arising in the central
airways [29], anatomically closer to micro-aspirations
than the peripheral airways, where adenocarcinoma
mostly arise. These histology-specific differences should
strengthen the reason for further studies of antireflux
surgery and lung cancer.
Two cohort studies have found an increased risk of
lung cancer in patients with GERD, which remained
after controlling for tobacco smoking [17,18]. The
slightly lower risk of lung cancer among non-operated
GERD-patients compared with the background popu-
lation in the present study was unexpected. Specula-
tively, the above-mentioned vast use of antireflux
medication (mainly proton pump inhibitors) in non-
operated GERD patients could possibly contribute to
this finding. Although antireflux medication does not
prevent airway micro-aspiration, it does reduce the
acidity of the refluxate, which could theoretically
decrease potential oncogenic inflammatory insults in the
lungs. Individuals with GERD who seek in-hospital our
outpatient specialised care might have greater health
consciousness and thus may be more likely to take
antireflux medication to alleviate their symptoms, less
likely to smoke or more likely to stop smoking
compared with the background population.
In conclusion, this large and population-based cohort
study in the five Nordic countries suggests that GERD-
patients who undergo antireflux surgery have a
decreased risk of small cell carcinoma and squamous cell
carcinoma, but not of adenocarcinoma of the lung.Author involvement
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